Xinhua News Agency reported that the results of the tenth batch of national organized Pharmaceutical centralized volume-based procurement have recently been officially announced. So far, this national action that has continued for six years has cumulatively procured 435 kinds of Pharmaceuticals, benefiting a large number of patients. However, it is also important to note that although the prices of procured Pharmaceuticals have decreased, the quality of Pharmaceuticals should not decline. Xinhua pointed out that Pharmaceutical procurement cannot be limited to 'whoever offers the lowest price wins'; strict quality assurance is a prerequisite. While carrying out the consistency evaluation of quality and efficacy in advance, real-world studies on the procured Pharmaceuticals should be continuously conducted to strengthen supervision and prevent sacrificing quality for price; promote the wide clinical entry of Pharmaceuticals with different mechanisms of action, better efficacy, and more convenient use in the same treatment field, allowing for an upgrade in the quality of medication.